|
|
2525 28th St., Suite 200
Boulder, CO 80301 USA
phone:+1 720 564 9100
fax:+1 720 564 9191
|
|
| Symbol |
PHRM |
| Exchange |
NASDAQ |
| Founded |
1999 |
| Employees |
166 |
|
|
| www.pharmion.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Products for the treatment of hematology and oncology |
|
| Management |
| Patrick J. Mahaffy, President and Chief Executive Officer; Director; Erle T. Mast, Executive Vice President, Chief Financial Officer; Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President, Chief Medical Officer; Gillian C. Ivers-Read, Executive Vice President, Development Operations; Michael Cosgrave, Chief Commercial Officer; Barrie L. Alioth, Vice President, Strategic Planning
Jay T. Backstrom, MD, MPH, Vice President, Global Medical and Safety; Joe Como, Vice President, Global Manufacturing; Jeffrey P. Davis, Vice President, Information Technology; Steven DuPont, Vice President, General Counsel; Pam Herriott, Vice President, Human Resources |
| |
|
|
|
|
|
|
|
| Keywords |
| hematology, oncology, leukemia, pharmaceutical |
|
|
|
| Description |
|
Pharmion is a global pharmaceutical company that is dedicated to the hematology and oncology communities. The Company works in partnership with a network of scientific and clinical advisors to identify and develop products for the global hematology and oncology markets. |
|
| Products / Services |
Pharmion is currently developing Vidaza, a chemotherapeutic for myelodysplastic sundrome, a type of leukemia. Pharmion has acquired rights to two marketed products, Innohep and Refludan. It also has two products, Thalidomide Pharmion 50 milligrams (mg) and Vidaza, in advanced stages of development. With its combination of regulatory, development and commercial capabilities, the Company intends to continue to build a balanced portfolio of approved and pipeline products targeting the hematology and oncology markets.
|
|
| Market / Customers |
The Company has established its own regulatory, development and sales and marketing organizations covering the United States, Europe and Australia. It has also developed a distributor network to serve the hematology and oncology markets in 19 additional countries throughout the Middle East and Asia.
|
|
| Competitors / Substitutes / Alternatives |
Competitors include Millennium Pharmaceuticals Inc., Celgene, Aventis, Pharmacia Corporation, Sonfi-Synthelabo and GlaxoSmithKline plc.
|
|
| Status |
| European thalidomide sales should be the biggest source of revenue growth for Pharmion over the next two years. Although never approved such an indication, thalidomide has been used in Europe for years to treat multiple myeloma. There are approximately 10 million capsules consumed per year. At Pharmion's price of $10 per capsule, this would translate to a $100 million opportunity. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
